Unfortunately, that wasn't even one of my proposed explanations.
I guess my question would be this: if that is the case, WHY is it the case? IOW, why would such a heavyweight "subcontract" out such things? I can think of only two explanations: 1) TEVA does not have relevant reverse-engineering expertise, and 2) TEVA does not have appropriate manufacturing facilities.
I'm sorry if I'm way off. I'm very interested, but also struggling to reach a deeper level of understanding about biotech matters.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.